Sol Gel Technologies Ltd (SLGL) Stock AnalysisSLGLStock AnalysisSol Gel Technologies Ltd

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sol Gel Technologies Ltd is not a good buy right now due to a significant recent revenue decline of 96%, leading to a net loss of $3.68 million in Q2 2026. Despite a strong historical performance with a 190.34% increase over the past year, the current RSI of 24.602 indicates oversold conditions, suggesting potential for a rebound but also significant risk. The main risk is the company's current price of $68.81, which is still high compared to its forward P/E of 9.3371, indicating that the stock may be overvalued given its recent financial struggles.

4 analysts cover SLGL: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.